ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why Regorafenib is on this study

  • The record lists it as a treatment.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 2, 2026, 5:24 AM UTC
  • The role rule says the same.
  • So Regorafenib's page lists this study under “Testing it”.
9 links0 made here, not in the record13 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule based
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT04879368RegoNivo vs Standard ofCare Chemotherapy in AGOCAustralasian Gastro-IntestinalPhase 3 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSNeoplasm MetastasisThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionAdenocarcinomaThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.CarcinomaThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSRegorafenibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedNivolumabIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorIrinotecanIntervention entry›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparatorINT000593Entry “Trifluridine/Tipracil”, read b…›Nov 2 · Claude Opus 5.5 · ComparatorNov 18 · Rule based · ComparatorComparator

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2RegorafenibClaude Opus 5.5TestedCurrent
Nov 2NivolumabClaude Opus 5.5TestedCurrent
Nov 2DocetaxelClaude Opus 5.5ComparatorCurrent
Nov 2PaclitaxelClaude Opus 5.5ComparatorCurrent
Nov 2IrinotecanClaude Opus 5.5ComparatorCurrent
Nov 2INT000593Claude Opus 5.5ComparatorCurrent
Nov 18RegorafenibRule based · role ruleTestedAgrees
Nov 18NivolumabRule based · role ruleTestedAgrees
Nov 18DocetaxelRule based · role ruleComparatorAgrees
Nov 18PaclitaxelRule based · role ruleComparatorAgrees
Nov 18IrinotecanRule based · role ruleComparatorAgrees
Nov 18INT000593Rule based · role ruleComparatorAgrees
As of nowNeoplasm MetastasisRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.